Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Cipher Pharmaceuticals Inc. (T:CPH)

Business Focus: Pharmaceuticals (NEC)

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for CPH within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Mar 14, 2024 17:00 ET
Read full article
Mar 08, 2024 06:00 ET
Cipher Pharmaceuticals Schedules Q4 2023 Earnings Release and Conference Call
MISSISSAUGA, ON, March 8, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the fourth quarter and full year of 2023 after the market close on Thursday, March 14, 2024. The Company will also hold a conference call on Friday, March 15 at 8:30 ET to discuss the results and corporate developments.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.02
--
--
Price to Sales - TTM
7.93
3.89
3.28
Price to Book - most recent quarter
2.08
2.66
1.97
Price to Cash Flow per share - TTM
7.76
7.31
9.65
Price to Free Cash Flow per share - TTM
10.58
19.27
12.19
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 15, 2024115,254-864
Feb 29, 2024116,118-12,393
Feb 15, 2024128,511-6,752
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

See business summary

 

Twitter

Search (past week) for $CPH.CA

  • No tweets found